Gopeshwar Narayan

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Cancer Res 64:2994-7. 2004
  2. pmc Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
    Pulivarthi H Rao
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    BMC Cancer 4:5. 2004
  3. pmc Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    Mol Cancer 5:16. 2006
  4. pmc Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003
  5. pmc Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, New York, USA
    Mol Cancer 7:58. 2008
  6. pmc Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 48:983-92. 2009
  7. doi request reprint Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 47:755-65. 2008
  8. doi request reprint PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis
    Gopeshwar Narayan
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY
    Genes Chromosomes Cancer 52:1030-41. 2013
  9. pmc Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Mol Cancer 3:16. 2004
  10. ncbi request reprint Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, NY 10032, USA
    Genes Chromosomes Cancer 46:373-84. 2007

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Cancer Res 64:2994-7. 2004
    ..Thus, these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols...
  2. pmc Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
    Pulivarthi H Rao
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    BMC Cancer 4:5. 2004
    ..Therefore, genetic characterization is essential for understanding the biology and clinical heterogeneity in cervical cancer (CC)...
  3. pmc Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    Mol Cancer 5:16. 2006
    ..Slit genes mediate their effect by binding to its receptor Roundabout (Robo). These genes have shown to be inactivated by promoter hypermethylation in a number of human cancers...
  4. pmc Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003
    ..Although a host of genetic alterations have been identified, molecular basis of CC development is still poorly understood...
  5. pmc Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, New York, USA
    Mol Cancer 7:58. 2008
    ..These changes may possess oncogenic properties by deregulating tumor-related genes. Gain of short arm of chromosome 5 (5p) is the most frequent karyotypic change in CC...
  6. pmc Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 48:983-92. 2009
    ..Our studies demonstrate that inactivation of PCDH10 may be a critical event in CC progression and form a potentially useful therapeutic target for CC...
  7. doi request reprint Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 47:755-65. 2008
    ..Our findings implicate a role for these genes in CC tumorigenesis, represent an important step toward the development of clinically significant biomarkers, and form a framework for testing as molecular therapeutic targets...
  8. doi request reprint PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis
    Gopeshwar Narayan
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY
    Genes Chromosomes Cancer 52:1030-41. 2013
    ..Both T- and B-cell lymphoma cell lines harboring methylation-mediated inactivation of PCDH10 were resistant to doxorubicin treatment, suggesting that hypermethylation of this gene might contribute to chemotherapy response...
  9. pmc Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Mol Cancer 3:16. 2004
    ..Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. The genetic pathway(s) that determine the chemotherapy sensitivity in GCT remain largely unknown...
  10. ncbi request reprint Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, NY 10032, USA
    Genes Chromosomes Cancer 46:373-84. 2007
    ..These data, thus, form an important step toward the identification of biologically relevant genes in CC pathogenesis. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  11. doi request reprint Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance
    Gopeshwar Narayan
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 50:1043-53. 2011
    ....
  12. pmc Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions
    Hugo Arias-Pulido
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, 10032, USA
    Mol Cancer 1:3. 2002
    ..These data therefore suggest that loss of candidate tumor suppressor genes located on 5p is associated with the development of CC. However, the precise location of 5p deletions is not known...
  13. ncbi request reprint Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Oncogene 22:3489-99. 2003
    ..Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35-q36.1 and 2q36.3-q37.1 that are critical in CC development...
  14. pmc Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis
    Gopeshwar Narayan
    Department of Pathology and Cell Biology, Institute for Cancer Genetics, Columbia University Medical Center, 1130 St Nicholas Avenue, New York, NY, USA
    Future Oncol 6:1643-52. 2010
    ....
  15. ncbi request reprint Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology
    Efsevia Vakiani
    Department of Pathology, Columbia University, New York, NY 10032, USA
    Hematol Oncol 26:199-211. 2008
    ..Together, our results suggest that PTLD represent a distinct type of B-NHL deriving from an antigen experienced B-cell, whose evolution is associated with accrual of genetic lesions...
  16. pmc Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells
    Loren Michel
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:4459-64. 2004
    ..Thus, anaphase-promoting complex substrates exhibit distinct sensitivities in the presence of different MAD2 doses, which in turn determine MAD2's role as either a tumor suppressor or an essential gene...
  17. ncbi request reprint Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells
    Zao Zhong Su
    Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    J Cell Physiol 192:34-44. 2002
    ..In these contexts, one mechanism by which PEG-3 influences cancer progression may be by preferentially facilitating the development of genomic changes in evolving cancer cells...
  18. ncbi request reprint Comprehensive molecular cytogenetic characterization of cervical cancer cell lines
    Charles P Harris
    Laboratory of Molecular Cytogenetics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Genes Chromosomes Cancer 36:233-41. 2003
    ..This comprehensive cytogenetic characterization of eight CC cell lines enhances their utility in experimental studies aimed at gene discovery and functional analysis...
  19. ncbi request reprint Re: Detection of hypermethylated genes in women with and without cervical neoplasia
    Vundavalli V Murty
    J Natl Cancer Inst 97:1548; author reply 1548-9. 2005
  20. pmc The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers
    Enrique Zudaire
    Angiogenesis Core Facility, NCI, NIH, Gaithersburg, Maryland 20892 4605, USA
    J Clin Invest 118:640-50. 2008
    ..These results therefore demonstrate that AHRR is a putative new tumor suppressor gene in multiple types of human cancers...
  21. ncbi request reprint Renal oncocytomas with 11q13 rearrangements: cytogenetic, molecular, and immunohistochemical analysis of cyclin D1
    Jeffrey S Jhang
    Department of Clinical Pathology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, VC14 215, New York, NY 10032 USA
    Cancer Genet Cytogenet 149:114-9. 2004
    ....